GFP Adeno-Associated Virus ( AAV-NRTYS )

Vectors based on adeno-associated viruses (AAV) are considered safe and effective, and they have been used in many clinical trials. The various AAV serotypes vary greatly in tropism, but none are specific to a single tissue after systemic administration, which is the most advantageous mode of vector administration for most gene therapy applications. Mixing capsid subunits from different AAV serotypes can redirect and improve transduction of target tissues to some extent. However, due to the limited diversity of pre-existing capsid proteins, this approach rarely achieves true vector specificity. GFP AAV-NRTYS is a viral vector designed specifically for efficient gene delivery, especially targeting endothelial cells. The vector is a recombinant AAV with engineered capsids, derived from AAV serotype 2 (AAV2). The distinctive feature of this custom vector is the addition of a specific peptide sequence NRTYSSTSNSTSRSEWDNS at residue I588 of the capsid. This modification enhances the ability of the virus to transfect endothelial cells, a key cell type in the vasculature and in many pathological conditions such as cancer, cardiovascular disease, and inflammation.